-
Article
Open AccessHow risky is a second allogeneic stem cell transplantation?
There is no consensus on second allogeneic stem cell transplantation (alloSCT) indications in patients with hematologic malignancies relapsing after a first alloSCT. In historic publications, a very high non-r...
-
Article
Open AccessATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in E...
-
Article
Open AccessPTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice ...